Selective .beta.3 adrenergic agonists
CA 2312987 A1 · Owner: Eli Lilly And Company · Inventors: Crowell, Thomas Allan; Shuker, Anthony John; Jones, Charles David
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention is in the field of medicine particularly in the , treatment of Type II diabetes and obesity. More specifically the present , invention relates to selective .beta.3 receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and methods of treating Type II diabetes and obesity comprising administering , to a mammal in need thereof compounds of Formula (I) or a pharmaceutically , acceptable salt thereof. The variables in Formula (I) have the meanings defined therein.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 4, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 4, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 4, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.